Stockreport

IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026

Imunon, Inc.  (IMNN) 
PDF LAWRENCEVILLE, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherap [Read more]